NCT06392841 2026-04-08
HARMONY
Hoosier Cancer Research Network
Phase 2 Withdrawn
Clinical Trials
36 trialsNCT06692452 2026-04-01
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT06313996 2026-03-18
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Withdrawn
NCT06527690 2025-09-29
REPRESENTATION
Latin American Cooperative Oncology Group
Phase 2 Withdrawn
NCT06329830 2024-09-19
LUNAAR
Baptist Health South Florida
Phase 1/2 Withdrawn
NCT00488605 2023-08-03
H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis
University of New Mexico
Phase 3 Withdrawn
NCT05934097 2023-07-06
FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
Fate Therapeutics
Phase 1 Withdrawn
NCT04974996 2022-03-29
LOTIS-8
ADC Therapeutics S.A.
Phase 1 Withdrawn
NCT00006669 2021-10-27
Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma
Medstar Health Research Institute
Phase 2 Withdrawn
NCT04296578 2021-08-12
Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone
Stanford University
Phase 1 Withdrawn
NCT02605694 2021-03-17
FRESCO
SecuraBio
Phase 2 Withdrawn
NCT01415765 2019-12-17
MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn
NCT02182622 2019-06-19
LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel
Hackensack Meridian Health
Phase 1 Withdrawn
NCT02538926 2018-11-14
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
University of Washington
Phase 2 Withdrawn
NCT02763761 2018-10-09
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT02228512 2018-08-31
Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn
NCT00900445 2018-08-07
Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk Acute Lymphoblastic Leukemia
Children's Oncology Group
Withdrawn
NCT02702960 2018-06-15
Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Withdrawn
NCT02815059 2018-01-31
Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone
University of Utah
Phase 1 Withdrawn
NCT00983944 2017-11-30
Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Withdrawn
NCT02595242 2017-05-23
Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Withdrawn
NCT01087580 2017-03-03
Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer
Northwestern University
Phase 2 Withdrawn
NCT00513188 2016-12-15
Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma
University of Miami
Phase NA Withdrawn
NCT00598858 2016-12-08
2007-5904
University of California, Irvine
Phase 2 Withdrawn
NCT02380313 2016-10-06
Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone
GlaxoSmithKline
Phase 1 Withdrawn
NCT01539174 2016-03-03
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma
Fox Chase Cancer Center
Phase 2 Withdrawn
NCT01692483 2015-12-02
Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer
Janssen Pharmaceutica
Withdrawn
NCT01670084 2015-10-30
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
Mayo Clinic
Phase 2 Withdrawn
NCT00004039 2015-08-19
Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma
Hoag Memorial Hospital Presbyterian
Phase 2 Withdrawn
NCT02159690 2015-01-26
A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy
Johns Hopkins University
Phase 2 Withdrawn
NCT01814865 2013-12-20
Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer
British Columbia Cancer Agency
Phase 2 Withdrawn
NCT01750866 2013-10-16
Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer
Case Comprehensive Cancer Center
Phase 2 Withdrawn
NCT01478308 2013-03-06
Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer
New Mexico Cancer Research Alliance
Phase 2 Withdrawn
NCT00811031 2012-07-30
Preoperative Docetaxel for Localized Progressive Castration-resistant Prostate Cancer (CRPC)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00019409 2012-03-23
Radiation Therapy to the Head or Intrathecal Chemotherapy Plus High Dose Cytarabine in Preventing CNS Disease in Children With Acute Lymphoblastic Leukemia
National Institutes of Health Clinical Center (CC)
Phase 3 Withdrawn
NCT00110006 2010-06-11
Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma
Case Comprehensive Cancer Center
Phase NA Withdrawn